ArticleThe Journal of investigative dermatology2014
Recombinant filaggrin is internalized and processed to correct filaggrin deficiency.
Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- An Assessment of Administration Route on MSC-sEV Therapeutic Efficacy.Biomolecules · 2024Article
- Extracellular epimorphin impairs expression and processing of profilaggrin in HaCaT keratinocytes.Cytotechnology · 2023Article
- Circadian Oscillations in Skin and Their Interconnection with the Cycle of Life.International journal of molecular sciences · 2023Review
- Epicutaneous Sensitization and Food Allergy: Preventive Strategies Targeting Skin Barrier Repair-Facts and Challenges.Nutrients · 2023Review
- Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement.Frontiers in pediatrics · 2023Review
- The Discovery and Function of Filaggrin.International journal of molecular sciences · 2022Review
- Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies.Clinical reviews in allergy & immunology · 2021Review
- Cracking the Skin Barrier: Liquid-Liquid Phase Separation Shines under the Skin.JID innovations : skin science from molecules to population health · 2021Review
- New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression.Journal of clinical medicine · 2021Review
- Skin Disease Models In Vitro and Inflammatory Mechanisms: Predictability for Drug Development.Handbook of experimental pharmacology · 2021Article
- Tuning the Cell-Free Protein Synthesis System for Biomanufacturing of Monomeric Human Filaggrin.Frontiers in bioengineering and biotechnology · 2020Article
- Filaggrin and atopic march.Biochemia medica · 2019Review
- Review
- Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis.Clinical, cosmetic and investigational dermatology · 2017Article
- Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis.International journal of molecular sciences · 2016Review
- Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise.The British journal of dermatology · 2015Article
- Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis.The Journal of allergy and clinical immunology · 2014Review
- Skin barrier defects in atopic dermatitis.Current allergy and asthma reports · 2014Article
- Crossing barriers; restoring barriers? Filaggrin protein replacement takes a bow.The Journal of investigative dermatology · 2014Article
- Genotype Study of Filaggrin Gene Loss-of-Function Mutations in Central India Population with Atopic Dermatitis and Ichthyosis Vulgaris.Indian dermatology online journalArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to engineer a functional filaggrin (FLG) monomer linked to a cell-penetrating peptide (RMR) and to test the ability of this peptide to penetrate epidermal tissue as a therapeutic strategy for genetically determined atopic dermatitis (AD). A single repeat of the murine filaggrin gene (Flg) was covalently linked to a RMR motif and cloned into a bacterial expression system for protein production. Purified FLG+RMR (mFLG+RMR) was applied in vitro to HEK-293T cells and a reconstructed human epidermis (RHE) tissue model. Immunochemistry demonstrated RMR-dependent cellular uptake of FLG+RMR in a dose- and time-dependent manner in HEK cells. Immunohistochemical staining of the RHE model identified penetration of FLG+RMR to the stratum granulosum, the epidermal layer at which FLG deficiency is thought to be pathologically relevant. In vivo application of FLG+RMR to FLG-deficient flaky tail (ft/ft) mice skin demonstrated internalization and processing of recombinant FLG+RMR to restore the normal phenotype. These results suggest that topically applied RMR-linked FLG monomers are able to penetrate epidermal tissue, be internalized into the appropriate cell type, and be processed to a size similar to wild-type functional barrier peptides to restore necessary barrier function, and prove to be therapeutic for patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.